Q32 Bio
QTTB
52 hedge funds and large institutions have $26.7M invested in Q32 Bio in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 20 reducing their positions, and 8 closing their positions.
60% more capital invested
Capital invested by funds: $16.6M → $26.7M (+$10M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less funds holding
Funds holding: 53 → 52 (-1)
3.73% less ownership
Funds ownership: 69.1% → 65.37% (-3.7%)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
55% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$603K |
| 2 |
Renaissance Technologies
New York
|
+$148K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$101K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.5K |
| 5 |
Jane Street
New York
|
+$71.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Acorn Capital Advisors
New York
|
-$876K |
| 2 |
MAM
Monaco Asset Management
Monaco
|
-$735K |
| 3 |
TOCUITCONY
Trustees of Columbia University in the City of New York
New York
|
-$265K |
| 4 |
Millennium Management
New York
|
-$151K |
| 5 |
BlackRock
New York
|
-$93.5K |
QTTB Hedge Fund Activity: Q4 2025 in Review
52 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q4 2025, worth a combined $26.7M — up 60% from $16.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of QTTB and 7 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 9 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $603K. The largest seller was Acorn Capital Advisors, cutting an estimated $876K.
- 52 institutional investors held Q32 Bio (QTTB) as of Q4 2025, down from 53 in Q3 2025.
- Funds reported $26.7M of Q32 Bio stock for Q4 2025, up 60% quarter-over-quarter.
- 7 funds opened new Q32 Bio positions in Q4 2025 and 8 closed out, a net change of -1 holder.
- The largest Q32 Bio buyer in Q4 2025 was Opaleye Management, an estimated $603K added.
- The largest Q32 Bio seller in Q4 2025 was Acorn Capital Advisors, an estimated $876K sold.
Based on aggregated 13F filings for Q4 2025.